Detail of "205923-56-4"

CAS Number:
205923-56-4
Name:
ImmunoglobulinG1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 g1-chain),disulfide with human-mouse monoclonal C225 k-chain, dimer
Synonyms:
C225; Cetuximab; EGFR antibody; Erbitux; IMC 225; IMC-C 225

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Roles of antibody therapy in lung cancer: All Rights Reserved. Roles of antibody therapy in lung cancer. Goto, Koichi; Saijo, Nagahiro (Higashi Hospital, Dep. of Respiratory Diseases, National Cancer Center, Japan). Bunshi Kokyukibyo, 10(6), 417-423 (Japanese) 2006 Sentan Igakusha.Several substances with their cas registry numbers 205923-56-4 and 183321-74-6 may be metioned in this study. CODEN: BUKOFC. ISSN: 1342-436X. DOCUMENT TYPE: Journal; General Review CA Section: 15 (Immunochemistry) A review discusses therapeutic application of antibodies such as Avastin, matuzumab, panitumumab, cetuximab, pertuzumab, and herceptin alone or combined with radio- or chemotherapy in treatment of lung cancer including non-small cell lung cancer. .

Cetuximab against EGF for advanced colorectal cancer: All Rights Reserved. 205923-56-4 and 216974-75-3 are also occured in this study. Cetuximab against EGF for advanced colorectal cancer. Takahari, Daisuke; Shimada, Yasuhiro (Central Hospital, Dep. of Gastroenterology, National Cancer Center, Japan). Igaku no Ayumi, 219(1), 29-33 (Japanese) 2006 Ishiyaku Shuppan. CODEN: IGAYAY. ISSN: 0039-2359. DOCUMENT TYPE: Journal; General Review CA Section: 15 (Immunochemistry) A review discusses therapeutic application of anti-EGF receptor monoclonal antibody, Cetuximab, alone or combined with CPT-11 or bezacizumab, in clin. trials for treatment of advanced colorectal cancer. .